Article

New Treatment Available for IBS-D in Adults

Author(s):

Global pharmaceutical company Allergan announced today the availability by prescription of Viberzi (eluxadoline), their first-in-class treatment for adult patients suffering from irritable bowel syndrome with diarrhea (IBS-D).

Global pharmaceutical company Allergan announced today the availability by prescription of Viberzi (eluxadoline), their first-in-class treatment for adult patients suffering from irritable bowel syndrome with diarrhea (IBS-D).

Few prescription treatment options that relieve both diarrhea and abdominal pain have been available for IBS-D patients. As such, two clinical trials indicated oral medication Viberzi relieves the primary symptoms of IBS-D — diarrhea and abdominal pain.

Contraindications for Viberzi include:

· Known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; structural disease of the pancreas.

· Alcoholism, alcohol abuse, alcohol addiction, or drink more than 3 alcoholic beverages per day.

· Severe hepatic impairment.

· A history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.

Also, the most commonly reported adverse events during testing were constipation, nausea, and abdominal pain.

William Meury, President and Executive Vice President, Branded Pharma, Allergan, commented, “We are excited about the launch of Viberzi, which addresses an unmet need among IBS-D patients seeking a treatment to manage their symptoms proactively.”

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Age, Race, Ethnicity Disparities Hinder Celiac Disease Screening, with Debra Silberg, MD, PhD
Lauren Collen, MD: Advanced Combination Therapy May Be Effective Option for Pediatric Refractory IBD
Lauren Collen, MD: Some Fragrances May be More Prevalent in Exposomes of Children with Crohn’s Disease
© 2024 MJH Life Sciences

All rights reserved.